Tesaro, Inc. (NASDAQ:TSRO) announced that it has submitted the New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist that is marketed in tablet formulation by TESARO in the United States under the brand name VARUBI®. The FDA approved VARUBI on September 1, 2015, for use in combination with other antiemetic agents in adults, for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
On Tuesday Tesaro, Inc. (NASDAQ:TSRO) share price closed at $41.55. Its return on equity (ROE) is -142.40%. Tesaro, Inc. (NASDAQ:TSRO) is -1.43% away from its 52 week high and its 52 week range is $29.51 – 66.95.
Oxford Asset Management acquired a new stake in shares of Array BioPharma Inc. (NASDAQ:ARRY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,064,085 shares of the biopharmaceutical company’s stock, valued at approximately $4,459,000. Oxford Asset Management owned 0.75% of Array Biopharma as of its most recent SEC filing.
Array BioPharma Inc. (NASDAQ:ARRY) traded 1.43 Million shares and its share price moved down -6.51% to close at $2.73. Company has 0.10% insider ownership. Array BioPharma Inc. (NASDAQ:ARRY) quarterly performance is -29.27% while its year to date (YTD) performance is -35.31%.
Alps Advisors Inc. reduced its stake in shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 10.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 73,548 shares of the biopharmaceutical company’s stock after selling 8,727 shares during the period. Alps Advisors Inc. owned 0.14% of Portola Pharmaceuticals worth $3,784,000 at the end of the most recent reporting period.
On Tuesday shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) ended up at $28.01. This year Company’s Earnings per Share (EPS) growth is -36.70% and next year’s EPS growth is 32.20%. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) weekly performance is -3.25%.
Shares of Louisiana-Pacific Corp. (NYSE:LPX) have earned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm. Four equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.55.
Louisiana-Pacific Corp. (NYSE:LPX) moved down -2.52% to close at $15.86 on 15 March. Its return on assets (ROA) is -4.00% while return on investment (ROI) is -3.40%. Louisiana-Pacific Corp. (NYSE:LPX) price to sales (P/S) ratio is 1.20.
On Mar 07, The American Society of Anesthesiologists (ASA) and CAE Inc. (NYSE:CAE) Healthcare announced a collaborative agreement to design and develop an interactive screen-based simulation product that will allow ASA members and other interested learners to supplement their continuing medical education (CME) and improve their management performance during anesthetic emergencies.
On 15 March CAE Inc. (NYSE:CAE) ended the day at $11.55. Company net profit margin stands at 9.60% whereas its return on equity (ROE) is 13.40%. CAE Inc. (NYSE:CAE) is -9.09% away from its 52 week high.